Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB’s Vimpat Falters In Diabetic Pain

This article was originally published in The Pink Sheet Daily

Executive Summary

Neuropathy filing is "not approvable" at FDA, but seizure indication is on track, firm says.

You may also be interested in...



UCB Takes Back EU Try With Vimpat

Withdrawal follows July “not approvable” letter in diabetic pain.

UCB Takes Back EU Try With Vimpat

Withdrawal follows July “not approvable” letter in diabetic pain.

UCB’s Keppra XR Wins FDA Approval

Extended-release tabs set to beat Keppra generics to pharmacy shelves.

Related Content

Topics

UsernamePublicRestriction

Register

PS068158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel